Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats-Reference-Cited by-同舟云学术

Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats

Published:2019-03-01 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Hrdlička Jaroslav,Neckář Jan,Papoušek František,Husková Zuzana,Kikerlová Soňa,Vaňourková Zdenka,Vernerová Zdenka,Akat Firat,Vašinová Jana,Hammock Bruce D.,Hwang Sung Hee,Imig John D.,Falck John R.,Červenka Luděk,Kolář František

Funder

Ministerstvo Zdravotnictví Ceské Republiky

Grantová Agentura, Univerzita Karlova

Dr. Ralph and Marian Falk Medical Research Trust

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference57 articles.

1. Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats.;Alánová;Vascul. Pharmacol.,2015

2. Transgenic rats carrying the mouse renin gene-morphological characterization of a low-renin hypertension model.;Bachmann;Kidney Int.,1992

3. Heart failure.;Braunwald;JACC Heart Fail.,2013